4 completed, 1 terminated. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
Follow High Cholesterol: new trials by email Literature Review of High Cholesterol trials Research Report on High Cholesterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia | Phase 3 | Completed | NewAmsterdam Pharma | 407 | 2024-03-01 | 2025-10-08 |
| Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Obicetrapib, Placebo - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 354 | 2022-07-25 | 2025-06-11 |
| Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Placebo, Obicetrapib - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 2530 | 2021-12-15 | 2025-09-19 |
| Technology-Assisted Cholesterol Trial in Consumers (TACTiC) 5 mg rosuvastatin calcium with a Web App (combination product) - High Cholesterol | Phase 3 | Completed | AstraZeneca | 1196 | 2021-07-08 | 2024-10-30 |
| Ezetimibe in Patients Hypo-responsive to Statins Ezetimibe, Atorvastatin - High Cholesterol, Coronary Artery Disease | Phase 3 | Terminated | University of California, San Diego | 2 | 2009-09-01 | 2019-08-21 |
Hypercholesterolemia (5) · Dyslipidemias (3) · Hyperlipoproteinemia Type II (3) · Atherosclerosis (2) · Coronary Artery Disease (1) · Genetic Diseases, Inborn (1) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Metabolic Diseases (1)
Hyperlipidemias (5) · Nutritional and Metabolic Diseases (5) · Lipid Metabolism Disorders (4) · Metabolic Diseases (4) · Arterial Occlusive Diseases (3) · Arteriosclerosis (3) · Cardiovascular Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Metabolism, Inborn Errors (3) · Vascular Diseases (3) · Dyslipidemias (2) · Genetic Diseases, Inborn (2) · Hyperlipoproteinemias (2) · Lipid Metabolism, Inborn Errors (2) · Coronary Disease (1)
Ezetimibe (2) · Atorvastatin (1) · Cholesterol Ester Transfer Proteins (1) · Combined Modality Therapy (1) · Rosuvastatin Calcium (1)
NewAmsterdam Pharma (3) · AstraZeneca (1) · University of California, San Diego (1)
United States (5) · Czechia (2) · Georgia (2) · Netherlands (2) · Poland (2) · Canada (1) · China (1) · Denmark (1) · Japan (1) · Norway (1) · South Africa (1) · Spain (1) · United Kingdom (1)
Marc Ditmarsch (2) · Marc Ditmarsch, MD (1) · Ori Ben-Yehuda, MD (1) · William C. Miller, M.D. (1)
PMID 38599257, PMID 38705341, PMID 40337982, PMID 40347969, PMID 41109840, PMID 41760952